RBC Capital Maintains Outperform on AbbVie, Raises Price Target to $280
آبفي
AbbVie, Inc. ABBV | 0.00 |
RBC Capital analyst Trung Huynh maintains AbbVie (NYSE:
ABBV) with a Outperform and raises the price target from $260 to $280.
RBC Capital Maintains Outperform on AbbVie, Raises Price Target to $280
AbbVie, Inc. ABBV | 0.00 |